All In Biotech

Drug Trial Radar · NCT01339260

An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting

A Phase III Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Study of the Efficacy and Safety of Oral Netupitant Administered in Combination With Palonosetron and Dexamethasone Compared to Oral Palonosetron and Dexamethasone for the Prevention of Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy

Last checked: Nov 20, 2026Latest source record: Nov 26, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,455 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,455

Actual

Start

Apr 2011

Primary completion

Nov 2012

Sponsor

Lead sponsor
Helsinn Healthcare SAIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Apr 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NETU-08-18 is a two-arm clinical study assessing efficacy and safety of a single oral dose of netupitant and palonosetron, two antiemetic drugs, versus oral palonosetron, both given with oral dexamethasone. The objective of the study is to demonstrate that netupitant and palonosetron are more effective than palonosetron alone, to prevent nausea and vomiting induced by moderately emetogenic cancer chemotherapy after administration of repeated cycles of chemotherapy.

Conditions

  • Chemotherapy-Induced Nausea and Vomiting

Interventions

  • Netupitant and PalonosetronDrug

  • PalonosetronDrug

  • DexamethasoneDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication, at Cycle 1Time frame: 25-120 hours

Locations

172 sites in 15 countries. Site status is shown where the registry gives one.

  • Anniston Oncology/Regional Medical Center

    Anniston, Alabama

  • Northwest Alabama Cancer Center

    Muscle Shoals, Alabama

  • Genesis Cancer Centre

    Hot Springs, Arkansas

  • Compassionate Cancer Care Medical Group Inc

    Corona, California

  • Compassionate Cancer Centre Medical Group

    Fountain Valley, California

  • American Institute of Research

    Los Angeles, California

  • Facey Medical Group

    Mission Hills, California

  • Compassionate Cancer Care Medical Group

    Riverside, California

  • American Institute of Research

    Whittier, California

  • Denver Health and Hospital Authority

    Denver, Colorado

  • Palm Beach Institute of Hematology and Oncology

    Boynton Beach, Florida

  • Baptist Cancer Institute

    Jacksonville, Florida

  • Deaconess Clinic Downtown

    Evansville, Indiana

  • Floyd Memorial Cancer Center of Indiana

    New Albany, Indiana

  • Kentucky Cancer Clinic

    Hazard, Kentucky

  • The John R Marsh Cancer Center

    Hagerstown, Maryland

  • Fallon Clinic at Worcester Medical Center

    Worcester, Massachusetts

  • Duke University Medical Center

    Durham, North Carolina

  • Piedmont Hematology Oncology Associates PA

    Winston-Salem, North Carolina

  • Tri-County Hematology and Oncolgy Associates Inc.

    Massillon, Ohio

  • Signal Point Clinical Research Center LLC

    Middletown, Ohio

  • Charleston Cancer Center

    Charleston, South Carolina

  • Charleston Hematology Oncology

    Charleston, South Carolina

  • Wellmont Medical Associates-Oncology and Hematology

    Bristol, Tennessee

  • Cancer Specialists of South Texas, P.A.

    Corpus Christi, Texas

  • The University of Texas Health Center

    Tyler, Texas

  • Northern Utah Associates Hematology / Oncology

    Ogden, Utah

  • Northwest Medical Specialties

    Tacoma, Washington

  • Hospital Italiano de Cordoba

    Córdoba, Argentina

  • Clínica Universitaria Reina Fabiola (Universidad Católica de Córdoba)

    Córdoba, Argentina

  • Instituto Oncológico de Córdoba - Sanatorio Aconcagua

    Córdoba, Argentina

  • Centro Oncológico Integral (COI)

    Mar del Plata, Argentina

  • Centro Oncologico de Integracion Regional (COIR)

    Mendoza, Argentina

  • Instituto Médico CER [Oncology]

    Quilmes, Argentina

  • Sanatorio Parque

    Rosario, Argentina

  • Centro Medico San Roque

    San Miguel de Tucumán, Argentina

  • ISIS Clinica Especializada

    Santa Fe, Argentina

  • Bobruisk Interregional Oncological Dispensary

    Babruysk, Belarus

  • Brest Regional Oncological Dispensary

    Brest, Belarus

  • Gomel Regional Clinical Oncological Dispensary

    Brest, Belarus

Showing 40 of 172 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.